LEXINGTON, Mass. — In a notable show of insider confidence, Jean-Jacques Bienaimé, a director at Keros Therapeutics, Inc., has purchased $10,270 worth of the company's common stock.

The open-market acquisition highlights executive backing as the clinical-stage biopharmaceutical developer continues advancing novel treatments for hematological and musculoskeletal disorders.

Market analysts typically interpret such insider buys as a positive signal, underscoring leadership's faith in the company's ongoing clinical milestones and long-term financial prospects.